{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:37Z","timestamp":1790352577104,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019229","name":"ViewRay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007959","name":"Chulabhorn Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007959","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010441","name":"Medizinischen Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cllc.2020.11.003","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T20:54:40Z","timestamp":1605732880000},"page":"332-340.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-884X","authenticated-orcid":false,"given":"Sebastian","family":"Regnery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Eichkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-7090","authenticated-orcid":false,"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7307-484X","authenticated-orcid":false,"given":"Katharina","family":"Weusthof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Antonia","family":"Dinges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami A.","family":"El-Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.11.003_bib1","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1002\/cncr.29640","article-title":"Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis","volume":"121","author":"Nanda","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2020.11.003_bib2","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.06.005","article-title":"Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review","volume":"129","author":"Kobiela","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2020.11.003_bib4","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT","volume":"20","author":"H\u00f6rner-Rieber","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.11.003_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.radonc.2019.10.004","article-title":"Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy","volume":"144","author":"Sharma","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2020.01.010","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure","volume":"145","author":"Pasalic","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.11.003_bib8","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMc1203770","article-title":"Central-airway necrosis after stereotactic body-radiation therapy","volume":"366","author":"Corradetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.11.003_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2020.11.003_bib10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2014.01.022","article-title":"Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a \u201cno fly zone.\u201d","volume":"88","author":"Chang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2020.11.003_bib11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2018.08.040","article-title":"Subgroup Survival Analysis in Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT","volume":"103","author":"Stam","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2020.11.003_bib13","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \"ultracentral\" non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib15","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.jtho.2016.11.369","article-title":"OA24.05 The Nordic HILUS-trial - first report of a Phase II trial of SBRT of centrally located lung tumors","volume":"12","author":"Lindberg","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.11.003_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2019.01.035","article-title":"Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours","volume":"134","author":"Lenglet","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","article-title":"The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.cllc.2020.11.003_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2008.06.1939","article-title":"Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation","volume":"74","author":"Guckenberger","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2020.11.003_bib21","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.jtcvs.2014.07.077","article-title":"Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality","volume":"148","author":"Pezzi","year":"2014","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2020.11.003_bib22","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jtcvs.2011.09.072","article-title":"Surgical treatment of lung cancer: predicting postoperative morbidity in the elderly population","volume":"143","author":"Rueth","year":"2012","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2020.11.003_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/09553002.2019.1552375","article-title":"Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis","volume":"95","author":"Rim","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.cllc.2020.11.003_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.11.003_bib25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib26","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.cllc.2017.08.002","article-title":"Survival impact of cardiac dose following lung stereotactic body radiotherapy","volume":"19","author":"Wong","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.11.003_bib27","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib28","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.prro.2018.11.005","article-title":"Tumor control and toxicity after SBRT for ultracentral, central, and paramediastinal lung tumors","volume":"9","author":"Nguyen","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1756-8722-3-39","article-title":"CyberKnife for hilar lung tumors: report of clinical response and toxicity","volume":"3","author":"Unger","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13014-016-0608-8","article-title":"Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases","volume":"11","author":"Lischalk","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2007.06.043","article-title":"Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy","volume":"70","author":"Onimaru","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2020.11.003_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijrobp.2005.11.028","article-title":"Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years","volume":"65","author":"Beitler","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2020.11.003_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2020.11.003_bib34","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.11.003_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial","volume":"4","author":"Henke","year":"2018","journal-title":"Adv Radiat Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420303363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:01Z","timestamp":1761505921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420303363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1525730420303363"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.11.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}